CDC42 GTPases (RHOJ,
CDC42, and RHOQ) are overexpressed in multiple
tumor types and activate pathways critical for tumor growth, angiogenesis,
and metastasis. Recently, we reported the discovery of a novel lead
compound, ARN22089, which blocks the interaction of CDC42 GTPases
with specific downstream effectors. ARN22089 blocks tumor growth in
BRAF mutant mouse melanoma models and patient-derived xenografts (PDXs) in vivo. ARN22089 also inhibits tumor angiogenesis in three-dimensional
vascularized microtumor models in vitro. Notably,
ARN22089 belongs to a novel class of trisubstituted pyrimidines. Based
on these results, we describe an extensive structure–activity
relationship of ∼30 compounds centered on ARN22089. We discovered
and optimized two novel inhibitors (27, ARN25062, and 28, ARN24928), which are optimal back-up/follow-up leads with
favorable drug-like properties and in vivo efficacy
in PDX tumors. These findings further demonstrate the potential of
this class of CDC42/RHOJ inhibitors for cancer treatment, with lead
candidates ready for advanced preclinical studies.